Statistical principles for analytical goal-setting were applied to two medical applications of drug-monitoringdata: (a) individualizingdosage requirements by reference to a population-based therapeutic range or to a patient-specific decision value determined by Bayesian decision analysis, and (b) prospective dosing by using pharmacokinetic principles. For application a, the analytical goal for total allowable analytical error (TE) was defined as the amount of error that does not decrease by more than 5% either the sensitivity (probability) for detecting dosage regimens that may require modification or the specificity for detecting appropriately dosed patients. The limiting factor in achievable sensitivity and specificity was the intra-individual variation of peak steady-state concentration (Cas), with the TE determined to be a CV of 4%. For application b, error-propagation rules were applied to a proposed prospective dosing scheme (J Pharmacokinet Biopharm 1978;6:135-51). The TE was determined to depend on the rate of theophylline clearance. For clearance rates sO.6 mL/(kg mm), the TE (CV) must not exceed 3% if the predicted infusionrate is to produce, with 95% confidence, a concentration within the therapeutic range.
Statistical principles for analytical goal-setting were applied to two medical applications of drug-monitoringdata: (a) individualizingdosage requirements by reference to a population-based therapeutic range or to a patient-specific decision value determined by Bayesian decision analysis, and (b) prospective dosing by using pharmacokinetic principles. For application a, the analytical goal for total allowable analytical error (TE) was defined as the amount of error that does not decrease by more than 5% either the sensitivity (probability) for detecting dosage regimens that may require modification or the specificity for detecting appropriately dosed patients. The limiting factor in achievable sensitivity and specificity was the intra-individual variation of peak steady-state concentration (Cas), with the TE determined to be a CV of 4%. For application b, error-propagation rules were applied to a proposed prospective dosing scheme (J Pharmacokinet Biopharm 1978;6:135-51). The TE was determined to depend on the rate of theophylline clearance. For clearance rates sO.6 mL/(kg mm), the TE (CV) must not exceed 3% if the predicted infusionrate is to produce, with 95% confidence, a concentration within the therapeutic range.
The objective evaluation of clinical status and the accurate, precise determination of drug concentrations in serum are paramount in the selection of an effective, nontoxic dosage regimen for drugs with a low therapeutic index.
Analytical reliability has increased considerably over the past years (1); however, analytical goals remain unclear. A survey of physicians' opinions on the requisite intralaboratory precision for good medical management documented that most required precision (CV) of 10%-15% or 20%-25% (2). However, opinions ranged from 5% to 50% and likely included the factors of 
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A principal application of a routine drug monitoring service is the determination of whether a standardized dosage regimen produces a drug concentration in serum within the limits of a population-based therapeutic range. A widely used scheme for adjustment of theophylline dosage dictates a decrease in dose by 10% if the peak steady-state concentration is 20-25 mgIL; the dose should be increased 25% if the concentration is 7.5-10 mgfL (9). Alternatively, Bayesian decision analysis allows the selection of a decision value that is patient-specific (12); the selection depends on the physician's estimated risk of toxicity before the theophylline test is done (prior or pretest probability) and the probability that a patient has toxicity for a theophylline concentration within a specific range (posterior probability).
Given that the patient's steady-state theophylline concentration exceeds or is equal to a certain decision value, test sensitivity is defined as the probability that the theophylline concentration will be measured as such. Test specificity is the probability that a steadystate theophylline concentration within a therapeutic range will be measured as such. Sensitivity and specificity are a function of analytical error and of intraindividual variability of steady-state concentrations in serum and can be determined 
CVa2
, is defined as CVa2 = CV,,2 + CVb2, where CV is the within-run relative standard deviation and CVb is the between-run relative standard deviation attributable to random inaccuracy (see Discussion). Systematic error attributable to assay nonspecificity is assumed to equal zero. The sensitivity and specificity were plotted as a function of total analytical error, expressed as the CV, and of the deviation of the steady-state concentration in serum from the limits of the therapeutic range (see Figures 1 and 2) .
The analytical goal for "total allowable" error (CVa) was determined as the amount of error that does not decrease by more than 5% either the sensitivity in detection of a dosage regimen that may require modification or the specificity for detection of appropriately dosed patients.
Prospective Dosing
The clinical usefulness of prospective dosing techniques depends on their ability to predict a drug dosage that will produce a steady-state concentration within the drug's therapeutic range. Analytical performance requirements for the prospective determination of theophylline dosage were determined through an analysis of the propagation of error incurred from the use of theophylline assay results to estimate pharmacokinetic parameters.
The commonly used method of Chiou et al. (14) for prospective dose determination requires determination of the theophylline concentrations in two serum specimens collected over a period of about one half-life of the drug. Theophylline clearance is determined from the expression
where Cl(e) is the estimated theophylline clearance (L/h), R is the initial theophylline infusion rate (mg/h), V, is the volume of distribution (L), and C1 and C2 are the theophylline concentrations (mgIL) in samples col-(1) lected at times t1 and t2 (h). if the estimated steady-state concentration, determined as Css(e) = R/Cl(e), is not within the therapeutic range, a new infusion rate to (2) achieve the targeted theophylline concentration in serum [Cas (target)] is then determined by using R = Cl(e) C (target).
The variability of the clearance estimates as a function of analytical error in determining the concentration of theophylline in serum was determined by applying the appropriate error propagation rule (15) to the expression used for estimation of clearance:
The range of infusion rates that results from uncertainty in Cl(e) was determined by Rh = Cl(e)h -C(target) and R1 = C1(e)1. C(target), where Rh, R1, Cl(e)h, and Cl(e)1 are the upper and lower 95% confidence limits of R and Cl(e), respectively.
The distribution of steady-state theophylline concentrations, which result from the uncertainty in the estimation of R, is characterized by SD = 0.25(Rh -R1)/Cl, where Cl is the distribution mean ("true" clearance), assumed in this analysis to be equal to Cl(e). The analytical goal for total allowable error of theephylline determination when the determination is used for prospective dosing is defined as the assay reliability required to predict, at the 95% confidence level, an These probability curves,determinedby using equation 1 (seetext) and an estimate of Intra-individual biological vanation of peak Cm equalto 5.8%, illustrate the probability that the theophlllne assay will detect a dosage regimenthat may require adjustmenteither downward (left) or upward (right) infusion rate that will produce steady-state theophylline concentrations within the therapeutic range.
Resufts
Decision values: The limiting factor in the ability of the theophylline assay to discriminate between a therapeutic and a nontherapeutic concentration is the intraindividual variation of the steady-state peak concentration. With analytical error equal to zero, the probability of reporting a theophylline concentration as >20 mgfL for an individual with a steady-state concentration equal to 21.0 mg/L is 79%; the probability is increased to 99.8% for a steady-state concentration equal to 24.0 mgfL (Figure 1) . As expected, the sensitivity of detection of inappropriate dosing decreases with increasing analytical error: If a specimen contains 22 mg of theophylline per liter, the probability that an assay result will exceed 20 mg/L is 90%, 78%, or 71% when the CV of the assay is 4%, 10%, or 15%, respectively. As illustrated in Figure 1 , there is a higher probability for detection of There is little loss of specificity (Figure 2 ) or sensitivity (Figure 1) (14) for prospectivedosing analysis, therefore, was performed by using clearances of 0.23, 0.65, 1.40, and 1.70 mL'(kg'min) (18) . Figure 3 can be used to define the assay precision required to achieve an acceptable level of uncertainty in prospective steady-state concentration. As an example, if the desired Cas is 15 mgfL and the physician needs to be assured at the 95% confidence level that the estimated infusion rate will produce a steady-state concentration within the therapeutic range of 10-20 mgfL, then the acceptable uncertainty of Cas is determined to be 15 ± 5 mg/L or CV = 100 x [(20 -10)141/15 = 16.6%. lithe only source of error in the Chiou scheme is in the theophylline determination, the required analytical precision (CV) is determined to be 2.5%, 3.7%, 11.6%, and 18.0% for clearance rates of 0.23, 0.65, 1.4, and 1.7 mL/(kg mm), respectively.
DIscussIon
The consensus opinion of the 1976 Aspen Conference participants was that "analytical goals can only be defined in terms of the needs for patient care" (5). Definition of analytical performance requirements in these terms presumes an understanding of the way physicians perceive and react to laboratory data. However, conceptualization of the diagnostic process has been very difficult (19,20) , and the statistical principles relating analytical performance requirements to diagnostic efficacy have been criticized as being insensitive to several factors involved in the process (21) .
Clinical use of drug-monitoring data is unique in that the physician is provided objective criteria for adjustment of a therapeutic regimen. An understanding of the probable course of action alter the review of clinical status and drug concentration data renders the statistical principles described by Harris (11) suitable for assessment of analytical performance requirements.
A majority of the attempts at analytical goal-setting in clinical chemistry-whether with methods embodied in statistical analysis of diagnostic efficacy (11, 22), physician surveys (2, 23), or determination of the testing "state of the art" performance (24, 25)-have concentrated on requirements for analytical precision. A source of error that has traditionally been included in measures of imprecision is "random" inaccuracy (26, 27) . This type of systematic error is primarily due to variability of day-to-day or long-term method calibration, variability of reagent integrity (e.g., lot-to-lot variability), assay susceptibility to changing laboratory environmental conditions, and variable instrument performance. Random inaccuracy differs from "inherent" inaccuracy, which is due to a lack of assay specificity.
Guidelines for tolerable inaccuracy in the determination of selected analytes, derived from "state of the art" analytical performance characteristics and generally expressed as a percentage of the "true" analyte concentration, have been proposed for the "inherent" inaccuracy component of systematic error (28, 29) . Such guidelines may be acceptable as accuracy performance standards for methods as they currently exist; however, the absence of inherent systematic error is the only conceivable goal.
Analytical goals for accuracy, therefore, should deal with the tolerable variability of the random systematic error, the distribution mean of which must be zero. By equating the "total error" of theophylline determinations, which is a composite of random and systematic errors, to a proposed clinically acceptable upper limit of 4%,! have implicitly assumed that the inherent systematic error is zero and have proposed that the upper limit of variability of both random imprecision and random inaccuracy errors be 2.8%. The requirement that CVb not exceed is consistent with the industry qualitycontrol standard that the limits for variation betweenruns are based on variation within-run (16). The quality-control system originally proposed by Levey and Jennings (30) was designed to detect between-run variation in excess of that predicted by within-run precision performance. Only when the procedure was reproducible from run to run was the analytical system considered to be in control. The use of analytical procedures that are insensitive to those factors that frequently produce significant run-to-run variability will ensure uniformity of assay performance characteristics among analytical systems and laboratories.
An important medical application of drug monitoring data is the prospective dosing of a therapeutic agent. The Chiou technique was selected as a representative example of the pharmacokinetic approaches to individualized dosing. Chiou et al. (14) have defined the optimal conditions for the use of their proposed method and stated that the CV of the drug determination should be <5-6%.! have shown that the analytical performance requirements vary with theophylline clearance rate and that for rates sO.6 mL/(kg -mm) the total analytical error should not exceed 3%.
The error propagation analysis was performed with the assumption that the only source of error was in the determination of drug concentration. This, however, is generally not the case; the errors associated with the sampling time interval and the accuracy of volume of distribution estimates may have a significant effect on the reliability of the prospective dosing technique (14,  31) . Estimates of the magnitude of these model-dependent errors are required to further refine requirements for analytical reliability.
In conclusion, analytical goals must comply with the needs of the specific medical application. To derive full benefit from clinically acceptable analytical methods, one must also control the pre-analytical variables associated with a therapeutic drug monitoring service. Reports of inconsistent drug-dosing schedules (32), improperly timed collection of samples (33), and inaccurate recording of collection times and amount of drug administered (34) all negate the utility of the service. These deficiencies in the application of therapeutic drug-monitoring principles may account for the widely varying estimates of intralaboratory precision required for good medical management (2). Beardsley et al. (35) concluded from a retrospective study of how drug determinations were used by physicians that the availability of test results did not improve patient care. Clearly, to justifr the cost in terms of effort, time, and money expended for improvement of existing technology for drug determination, continued education of all appropriate health-care personnel is required to ensure effective implementation of the therapeutic drug-monitoring service.
